View : 46 Download: 0

Ubiquitin–proteasome system (UPS) as a target for anticancer treatment

Title
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
Authors
Park J.Cho J.Song E.J.
Ewha Authors
송은주
Issue Date
2020
Journal Title
Archives of Pharmacal Research
ISSN
0253-6269JCR Link
Citation
Archives of Pharmacal Research vol. 43, no. 11, pp. 1144 - 1161
Keywords
CancerDeubiquitinating enzymes (DUBs)E3 ligaseProteasomeSmall molecule inhibitorsUbiquitin–proteasome system (UPS)
Publisher
Pharmaceutical Society of Korea
Indexed
SCIE; SCOPUS; KCI scopus
Document Type
Review
Abstract
The ubiquitin–proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics. © 2020, The Pharmaceutical Society of Korea.
DOI
10.1007/s12272-020-01281-8
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE